Friday, 13 Jul 2018

You are here

The RheumNow Week in Review – 21 April 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

  1. Long term followup of RA pts on Norfolk registry demonstrate better SURVIVAL when DMARDs are started early (<6 mos) https://t.co/Wy2OVFuw7l
  2. How Pfizer makes most of its $52.8 billion in 2016 - Surprisingly most from Prevnar 13 at $5.7 bill/year! https://t.co/bSy2GjLlj9
  3. Neutrophil to Lymphocyte ratio useful in assessing SLE w/ lympho/leukopenia from Rx or SLE? High (>2) w/ Dz activity https://t.co/NrbQaQ2xtA
  4. Acute Arthritis study shows ultrasound gout findings show sensitivity/specificity for 1) double contour 42/92%, 2) Intraarticular aggregates 58/92%, and 3) tophi 40/100.; all with a PPV 88-100% https://t.co/pf2T3JBAeU
  5. In animal models, high fat, high carbohydrate diet (junk food) promotes cartilage damage and osteoarthritis. https://t.co/70KgIrzh74
  6. Corrona study 1,567 PsA shows patients w/ dactylitis or enthesitis had more Dz activity, Pain, Fatigue, low work,HAQ https://t.co/2UcTOZKhYf
  7. Osteoarthritis Initiative 4367 pts shows 15% w/ recurrent falls, increased by 22-25% w/ opioid or antidepressant use https://t.co/LiIEANObvj
  8. Lyme disease hits 2016 record high in Maine; 1464 cases, up by 21% from 2015. Most increased Penobscot Co since 201… https://t.co/3LPj5wdisM
  9. Data from OP/OA mtg in Italy says Knee Osteoarthritis is associated wth a 13% higher risk of developing hypertension (P=.03) https://t.co/pEKJH0R7wj
  10. Norway population study shows self-reported dx of RA & AS highly inaccurate, 19% RA, 16% AS verified by hosp records https://t.co/zc2zIb1ZZY
  11. FDA Delays Baricitinib Decision
  12. The Cost of Not Taking Medicine
  13. Anti-IL-23 Therapy Effective in Crohn's Disease
  14. Paradoxical Toxicities with TNF Inhibitors
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

I am working in locum in Wisconsin and note that the EHR frequently lists a "problem" (not diagnosis) of Lyme disease. The majority of such patients have poorly documented disease manifestations with non-confirmatory serologies upon repeat or Western Blot. The majority are "diagnosed" and empirically treated in the ER or urgent care setting by a primary care doc based on non-specific complaints (when I started practice in 1978 such patients were labeled "chronic brucellosis", now they are labeled "chronic Lyme disease). Hence I am slow to accept any "reports" regarding the incidence of Lyme disease. More likely its the incidence of mis-dagnosis of Lyme disease. A + PPD does not equate to active TB (only exposure), and +serolgy for Lyme does not equate to active disease, only expoure to B. Bergdorfi.

More Like This

The RheumNow Week in Review –Fateful Outcomes in Rheumatology (7.13.18)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  Fateful outcomes in Rheumatology, what happens to Seronegatives, IL-23 fails, MRI progression, Not all inflammatory back pain becomes SpA:

The RheumNow Week in Review – Life Savers for Rheumatologists (6.29.18)

Dr. Jack Cush reviews selected news and journal reports from the past week on RheumNow.com.

The RheumNow Week in Review – EULAR18 Epilogue (6.22.18)

Dr. Jack Cush reviews EULAR 2018 and the past week's news and reports from RheumNow.com, including DMARDs in OA, the price of Penicillamine, Infections when ANCA+, CV outcomes in gout, NSAIDs in Pregnancy and Seropostive vs. Seronegative Outcomes.

CDC Obesity Prevalence Higher in the Rural USA

MMWR reports that approximately 46 million persons (14%) in the United States live in nonmetropolitan counties, where there is a higher prevalence of obesity-associated chronic diseases such as diabetes, coronary heart disease, and arthritis. (Citation source: http://bit.ly/2lj5yql)

EULAR 2018 - Podcast from Day 4

This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.

Click HERE to listen.

You can also listen on iTunes, Soundcloud or Stitcher.